DUBLIN, Oct. 22, 2021 /PRNewswire/ — The "Tissue Diagnostics: Technologies and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global tissue diagnostics market should reach $6.4 billion by 2026 from $4.7 billion in 2021 at a compound annual growth rate (CAGR) of 6.0% for the forecast period of 2021 to 2026.
The report analyzes each market and its applications, regulatory environment, technologies involved, market projections and market shares.
The emerging markets discussed include countries such as India, China, South Korea, Taiwan, Africa, Australia, Brazil, and Russia, among others. The report also examines market drivers as well as restraints and challenges affecting its growth.
Further, the report also highlights the emerging products and technologies and associated start-ups that are likely to accelerate the growth of the industry through their best practices in the research and development of tissue diagnostic tests. Excluded from this study is diagnostic testing such as imaging, veterinary diagnostics and their associated products.
The most significant market trend during 2020 was the origin and global spread of COVID-19, the disease caused by the novel coronavirus. Originating in late 2019 in China, the virus quickly became a global pandemic. Global health organizations and diagnostic manufacturers quickly developed and approved tests for the virus. This effort overwhelmed all other trends in 2020. One effect of this activity was a complete halt of merger and acquisition activity among major diagnostic manufacturers in 2020.
Because of its large population and its position as a medical technology innovation hub, North America is the global leader in terms of tissue diagnostics utilization. It remains the largest market, accounting for roughly 42.0% of the total market in 2020. The emerging markets of India, China, Russia and Brazil are poised to grow at double-digit growth rates due to rising incomes, growing healthcare budgets and heightened health awareness among the population.
In Asia-Pacific, there is increasing demand for tissue diagnostic test devices, as more people are concerned about quality healthcare. Further, the expanding aging population is leading to a significant rise in the volume of clinical tests performed in laboratories. The Asia-Pacific region is currently dominated by Japan, with the largest share of revenues growing at a stable growth rate. In the coming years, however, the Asia-Pacific market is expected to be driven by emerging economies, such as China, followed by India.
The Report Includes:
Estimation of the market size and analyses of the global market trends, with data from 2018 to 2020, estimates for 2021 with a projection of CAGR through 2026
Market share analysis of tissue diagnostic testing based on type, application, end-user and geography
A detailed description of the three major tissue diagnostics tests, i.e., hematoxylin and eosin (H&E), immunohistochemistry (IHC) and in situ hybridization (ISH)
Description of molecular diagnostic tests including antigen tests, antibody (serology) tests and in vitro diagnostic testing, and information on alternative options for diagnostic tests
Details about the COVID-19 global pandemic, its testing basics and specific tests for the management of COVID-19 patients
Identification of new opportunities, challenges and technological changes within the industry
Assessment of regulatory structure, pricing and reimbursement scenario, pipeline analysis and FDA product approvals in 2020
Highlights
The general culture test segment of the global tissue diagnostics market is expected to grow from $3.0 billion in 2021 to $3.9 billion in 2026 at a CAGR of 5.4% for the forecast period of 2021 to 2026.
The AST/ID test segment of the global tissue diagnostics market is expected to grow from $1.1 billion in 2021 to $1.5 billion in 2026 at a CAGR of 7.1% for the forecast period of 2021 to 2026.
Company profiles of major players in the market, including Abbott Diagnostics Inc., Becton, Dickinson and Co., General Electric, Merck KGaA, Qiagen N.V. and Thermo Fisher Scientific Inc.
Companies Mentioned
Abbott Diagnostics Inc.
Agilent Technologies Inc.
Beckman Coulter (Part Of Danaher)
Becton Dickinson And Co.
Bio-Rad
Biomerieux
F. Hoffmann-La Roche Ltd.
General Electric
Hologic Inc.
Merck Kgaa
Ortho Clinical Diagnostics
Qiagen N.V.
Siemens Healthineers Ag
Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/r/43zrs8
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-tissue-diagnostics-technology-and-market-research-report-2021-2026-featuring-abbott-diagnostics-becton-dickinson-and-co-general-electric-merck-qiagen-and-thermo-fisher-scientific-301406546.html
SOURCE Research and Markets
Shares of online retail stocks were taking a beating in Friday trading, with Shopify (NYSE: SHOP) stock falling by 5.2% through 2:37 p.m. EDT, MercadoLibre (NASDAQ: MELI) down by 4.5%, and e-commerce leader Amazon.com (NASDAQ: AMZN) off by 2.3%. As it reported Friday morning, analyst Stephen Ju at Swiss mega-bank Credit Suisse cut his price target on Amazon shares by more than 10% to $4,200, based on his estimate that Amazon will earn only $70.98 per share this year and $79.83 per share next year. Credit Suisse's new earnings projections reflect a reduction of 12% this year, and a staggering 33% reduction in expectations for 2022.
The Dow Jones rallied despite Intel earnings. EV leader Tesla passed a buy point. Donald Trump SPAC exploded to a massive gain.
Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN) skyrocketed on Friday, as excitement for former President Donald Trump's new media company continued to build among investors. On Wednesday, Digital World Acquisition announced a deal to merge with Trump Media & Technology Group. The combined company intends to launch a new social network to compete with the likes of Facebook and Twitter.
Shares of a wide number of digital advertising stocks took it on the chin Friday. Programmatic advertiser PubMatic (NASDAQ: PUBM) was down as much as 14.3% on Friday, sell-side platform Magnite (NASDAQ: MGNI) was off by 13.8%, online advertising technology specialist Criteo (NASDAQ: CRTO) was down as much as 10.5%, and digital advertising kingpin The Trade Desk (NASDAQ: TTD) was off as much as 9.6%.
International Business Machines (NYSE:IBM) delivered another set of lackluster results on Wednesday when third quarter results were announced. While returns remain uninspiring, the current valuation may offer an opportunity.
The maker of plant-based meat substitutes released preliminary results for the third quarter, warning that its growth would fall far short of its forecast. Beyond Meat said in a press release that the company was reducing its third-quarter net revenue outlook after reviewing its preliminary results. This marks a sharp deceleration from the company's recent growth rate.
Matt Bryson, Wedbush SVP, Equity Research, discusses Intel Q3 earnings beat and weak future outlook amid the ongoing chip shortage.
ARK’s daily email disclosure revealed the firm has bought 2.1 million shares in Skillz, worth an estimated $20.8 million.
In this article, we discuss the 10 stocks to consider in the portfolio of Nancy Pelosi. If you want to skip our detailed analysis of these stocks, go directly to Nancy Pelosi Stock Portfolio: 5 Stocks To Consider. Former United States President Barack Obama had signed into law the Stop Trading on Congressional Knowledge (STOCK) […]
Tesla stock hit a new all-time high in Friday trading, and closed at a record. Shares also got a boost Friday from a credit upgrade at S&P. Tesla debt is now BB+ rated, one notch below investment grade. Tesla stock’s new 52-week intraday high is $910 on the nose.
David Tepper, billionaire investor and one of the world’s top hedge-fund managers, isn't a fan of the stock market, right now.
This tiny, money-losing Trump-linked software company has a stock that is surging, but what's behind all this PHUN?
Here's how to handle peak earnings week, with Apple and Microsoft among the many key reports. Can Trump SPAC stock DWAC keep moving?
Shares of fintech giant Square (NYSE: SQ) had fallen by more than 4% as of 11:27 a.m. EDT Friday after an analyst at Jefferies said they expect the company to miss earnings estimates in its upcoming quarterly report. When companies report earnings below the consensus estimate, their shares often decline in the short term, although post-report price moves are also dependent on lots of other factors including management's guidance and overall outlook. Further, while Jefferies expects Square to miss on earnings, the company also initiated coverage on Square earlier this month with a $300 price target.
Traders shrugged off Chipzilla's fantastic bottom-line profits and inspiring long-term growth plan to focus on the massive costs of bringing that vision to life.
Shares of AT&T Inc (NYSE: T) are trading slightly higher—although volatile— following better-than-expected third-quarter financial results. What Happened: AT&T reported quarterly adjusted earnings of 87 cents per share, which beat the estimate of 78 cents per share. The company reported quarterly revenue of $39.92 billion, which beat the estimate of $39.14 billion. Related Link: AT&T Shares Gain After Q3 Earnings, HBO Strength, Robust Full Year Outlook Cramer's Take: 'I'm willing to say this is
What happened Shares of IBM (NYSE: IBM) fell 9.5% on Thursday after the global technology company's third-quarter results came up short of investors' expectations. So what IBM's revenue inched up 0.
(Bloomberg) — Intel Corp. shares plummeted to their lowest close since December on Friday, after the chipmaker reported third-quarter results and detailed a spending plan that it said would pressure profitability over the next few years.Most Read from BloombergWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyThe Top Money Maker at Deutsche Bank Reaps Billions From SingaporeCities' Answer to Sprawl? Go Wild.One of California’s Wealthiest Counties Could Run Out of Water Next Sum
Just how much do Snap Inc.'s issues translate to the rest of the internet's major ad companies?
Shares of Progenity (NASDAQ: PROG) were up more than 24% on Friday. The biotech company is developing a test called Preecludia that rules out preeclampsia, a pregnancy-related blood pressure disorder, while also specializing in gastrointestinal drugs and oral biotherapies. The stock has been a favorite of retail investors looking for a short squeeze.